XAGE Carmell Corp Insider Trading

CEO Ram buys 689.7K shares at $0.29 in deeply unprofitable, micro-cap biotech down -95.6% from 52-week high.

Ajjarapu J. Ram, CEO of Longevity Health Holdings, purchased 689,656 shares at $0.29 for $200,000.24 on 2026-03-16, establishing a zero-to-689.7K position. The company is a micro-cap with a $668.3K market cap, having posted $-1.4M net income over its most recent full fiscal year while generating only $425.9K in latest quarterly revenue. The stock trades at $0.27 currently, down -95.6% from its 52-week high of $6.12, though up 6.7% over the prior 30 days. This inaugural insider purchase by the CEO occurs in a financially distressed shell-stage company; the transaction's modest dollar value relative to the company's revenue and the stock's positioning near multiyear lows warrant documentation but do not constitute a material market signal on their own.

Director Upton Richard A bought 5,000 shares of CTCX at $0.47 on 2024-09-13; stock down -91.2% from 52-week high.

Director Upton Richard A purchased 5,000 shares at $0.47 on 2024-09-13, increasing his holdings to 15,000 shares. The stock has collapsed to $0.43 (current price), down -91.2% from its 52-week high of $4.87, and his purchase price was reached after a -55.0% decline over the preceding 30 days. His prior trades at CTCX show a poor track record: of his 3 measurable prior purchases at this ticker, none achieved positive 90-day returns, with outcomes ranging from -22.3% to -78.7% over 90 days. His broader cross-ticker buy track record is similarly weak: 0 of 4 prior buys had positive 90-day returns, averaging -44.3%. The company is unprofitable (net income of $-3,304,538.00 over the latest full fiscal year) with minimal revenue of $12,320.00 in the latest quarter and a market cap of $8,989,325.01. While a cluster of 5 other insiders also bought within the past 14 days, Upton's own purchase pattern at this ticker shows consistent inability to time entry points favorably, raising questions about the quality of this incremental deployment.

Director Gregory Kathryn buys 1,260 shares of CTCX at $0.51; stock down 90.4% from 52-week high, 5-trade cluster pattern in past 14 days.

Gregory Kathryn (Director) purchased 1,260 shares at $0.51 on 2024-09-06, increasing holdings by 5.9% to 22,500 shares. The purchase occurs amid severe price pressure: CTCX trades at $0.47 current price, representing a 90.4% decline from its 52-week high of $4.87, with a 77.5% drop over 90 days. The company is unprofitable with a net income of $-3,304,538.00 for its most recent full fiscal year and latest quarterly revenue of $12,320.00 against a $9,825,541.29 market cap. Notably, five other insiders also bought within the past 14 days, establishing a cluster pattern. Kathryn's cross-ticker track record shows mixed outcomes (18 prior buys, 30-day average +5.3%, 90-day average -15.9%, 90-day win rate 30.00%), while his five recent CTCX purchases (2024-08-26 through 2024-08-30) remain too recent for outcome measurement. The timing of this cluster buy during a sustained decline in a distressed equity warrants scrutiny of the underlying business rationale.

Director Frisch buys 1,009 shares at $0.51; stock down -90.4% from 52-week high, $9.8M market cap, unprofitable fundamentals.

Frisch Scott M. purchased 1,009 shares at $0.51 on 2024-09-06, raising his holdings to 7,598 shares (+15.3% increase). The timing context is highly unfavorable: CTCX has declined -55.2% in the 30 days prior and -77.5% over 90 days, now trading -90.4% below its 52-week high of $4.87. At the same-ticker level, his two prior measurable purchases in December 2023 each posted negative 90-day returns (-10.6% and -2.6%), indicating his prior buys at this stock were not well-timed. Fundamentally, the company reported $12.3K revenue in the latest quarter with a -$3.3M net loss and an overall unprofitable year, yet the stock is still valued at $9.8M market cap. The buy occurs within a cluster pattern: 5 other insiders also purchased within the past 14 days, which at minimum establishes coordinated or synchronized activity rather than an isolated conviction signal.

CFO Bryan J. Cassaday bought 475 shares of CTCX at $0.46 on 2024-09-10; stock down 90.4% from 52-week high, insider's prior trades at ticker show 0% 90-day win rate.

Cassaday purchased 475 shares at $0.46 on 2024-09-10, increasing holdings to 4,250 shares (+12.6%), as CTCX trades at $0.47, down 90.4% from its 52-week high of $4.87. This purchase is part of a cluster: 5 other insiders also bought within the past 14 days. However, Cassaday's historical pattern at this ticker is concerning—his prior 4 measurable trades at CTCX show a 0% 90-day win rate, with purchases resulting in -81.1%, -78.7%, -74.9%, and -33.1% declines over 90 days. The company posted a net loss of $3,304,538 in the latest quarter and remains unprofitable on a full-year basis, with minimal quarterly revenue of $12,320. The convergence of a deeply depressed stock, an insider's repeated poor timing on prior trades at the same ticker, and fundamental losses suggests this filing merits close scrutiny of the company's financial position and the motivation driving continued insider accumulation.

Director Spenlehauer bought 1,009 shares of CTCX at $0.51; stock now $0.47, down 90.4% from 52-week high.

Spenlehauer Gilles (Director) purchased 1,009 shares at $0.51 on 2024-09-06, increasing his holdings by 15.3% to 7,598 shares. The stock has since declined to $0.47, representing a -90.4% drawdown from its 52-week high of $4.87 and a 30-day decline of -55.2% from purchase. At the same ticker, his prior two buys in December 2023 each showed 90-day losses (-41.3% and -35.2%), with 0 of 2 prior CTCX buys proving well-timed over 90 days. Importantly, the company is unprofitable with latest-quarter revenue of $12,320.00 and a full-year net income of $-3,304,538.00, and a cluster of 5 other insiders also bought within the past 14 days. The convergence of sharply negative price momentum, unprofitable fundamentals, a failed timing pattern at this ticker, and coordinated multi-insider buying amid distress suggests elevated risk.

Director Sturgeon bought 1,261 shares of CTCX at $0.51 on 2024-09-06; stock now $0.47, down 90.4% from 52-week high.

Sturgeon Patrick A, a director, purchased 1,261 shares at $0.51 per share on September 6, 2024, adding to his holdings after five consecutive buys over the prior five trading days (August 26–30). The stock has collapsed since: currently trading at $0.47 (down 90.4% from its 52-week high of $4.87) and down 55.2% in just 30 days. Carmell Corp is unprofitable, posting $-3.3M net income for its most recent full fiscal year on minimal $12.3K quarterly revenue, and carries a market cap of only $9.8M. The pattern of daily accumulation combined with cluster buying from 5 other insiders within 14 days suggests coordinated action, though the fundamental deterioration and severe price decline underscore the material risk underlying the position.

Director Scott M. Frisch bought 87 CTCX shares at $0.57; stock down -88.5% from 52-week high amid -$3.3M net loss and cluster buying.

Director Frisch Scott M. purchased 87 shares at $0.57 on 2024-08-30, increasing his holdings to 6,589 shares (+1.3% vs. pre-transaction). The transaction occurred as Carmell Corp (CTCX) trades at $0.56 current price, down -88.5% from its 52-week high of $4.87, with the stock declining -50.0% over the past 30 days and -78.4% over 90 days. The company's fundamentals are deteriorating: revenue stands at $12.3K in the latest quarter against a net loss of -$3.3M, with the company unprofitable over its most recent full fiscal year. Notably, this purchase is part of a cluster pattern with 5 other insiders also buying within the past 14 days. However, Frisch's prior trades at this ticker show poor timing outcomes: his 3 measurable prior buys at CTCX (in December 2023) all resulted in negative 90-day returns (-10.6%, -2.6%, -36.8%), with 0 of 3 well-timed at the 90-day mark.

Director Spenlehauer buys 87 CTCX shares at $0.57; stock down 88.5% from 52-week high, 5-insider cluster pattern emerges.

Director Gilles Spenlehauer purchased 87 shares at $0.57 on 2024-08-30, the third consecutive buy in two days, as part of a 5-insider cluster buy pattern within the past 14 days. The transaction comes as CTCX stock has declined 88.5% from its 52-week high of $4.87 and has fallen 50.0% over the past 30 days and 78.4% over 90 days. At Spenlehauer's prior trades at this ticker (December 2023 and recent August 2024 purchases), 0 of 3 measurable buys showed positive 90-day returns; his three December trades posted 90-day declines of -41.3%, -35.2%, and -57.6%. Carmell remains unprofitable with negative full-year net income of $-3,304,538.00 and latest quarterly revenue of only $12,320.00, constraining fundamental support for the depressed share price.

Director Gregory Kathryn buys 109 CTCX shares at $0.57; stock down -88.5% from 52-week high, -50.0% in 30 days, amid cluster of 5 other insider buys.

Gregory Kathryn purchased 109 shares on 2024-08-30 at $0.57, bringing holdings to 21,240 shares. The purchase occurs within a 5-day span of consecutive insider buys at the same ticker (2024-08-23 through 2024-08-30), with 5 other insiders also buying within the past 14 days. CTCX trades at $0.56 currently, down -88.5% from its 52-week high of $4.87 and down -50.0% over the past 30 days. The company reported $12.3K in latest quarterly revenue against a net loss of $-3.3M and operates at a $11.7M market cap while unprofitable. Across Gregory's cross-ticker track record, 17 prior buys averaged -15.9% return over 90 days with a 30.00% win rate, providing limited precedent for timing accuracy. The cluster buy pattern and consecutive purchases at a severely depressed valuation warrant observation of underlying catalysts or circumstances motivating simultaneous insider acquisition.